Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

5.230 +0.260 (+5.24%)
Streaming Delayed Price Updated: 2:16 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present at Jefferies London Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn Guidance ↗
 
Via Benzinga
News headline image
Recap: Arbutus Biopharma Q1 Earnings ↗
 
Via Benzinga
News headline image
Arbutus Biopharma's Earnings Outlook ↗
 
Via Benzinga
News headline image
Why Arbutus Biopharma Stock Is Sinking Today ↗
After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump. 
Via The Motley Fool
News headline image
Earnings Scheduled For February 29, 2024 ↗
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
News headline image
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute ↗
Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Participate in Two Upcoming Investor Conferences
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
3 Stocks to Buy For the COVID Resurgence
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting 
Via MarketBeat
News headline image
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Appoints Two New Executives
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present at Jefferies Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Present at JMP Securities Life Sciences Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
From Arbutus Biopharma Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.